Camrelizumab (SHR-1210)

DRUG2 trials

Sponsors

Peking Union Medical College Hospital, Fudan University

Conditions

Metastatic Breast CancerRecurrent Platinum-resistant Ovarian CancerTriple Negative Breast Cancer (TNBC)

Phase 2

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Peking Union Medical College HospitalRecurrent Platinum-resistant Ovarian Cancer

Start: 2019-10-28End: 2022-06-30Target: 28Updated: 2021-03-16

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Not yet recruitingNCT06731153

Fudan UniversityMetastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)

Start: 2024-12-31End: 2027-12-31Target: 40Updated: 2024-12-12